Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 175

Results For "API"

3145 News Found

Biotium introduces novel antibody labeling Kits for efficient labeling of IgM antibodies
News | June 27, 2023

Biotium introduces novel antibody labeling Kits for efficient labeling of IgM antibodies

Mix-n-Stain CF Dye IgM Antibody Labeling Kits address longstanding challenges for labeling IgM antibodies by offering efficient and convenient conjugation with bright CF Dyes


Sun Pharma presents data from Phase 1 studies of GL0034
News | June 26, 2023

Sun Pharma presents data from Phase 1 studies of GL0034

GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity


Carbogen Amcis Manchester bags award for  manufacturing performance
News | June 25, 2023

Carbogen Amcis Manchester bags award for manufacturing performance

Carbogen Amcis Manchester won the industry award in recognition of its efficiency improvement program implemented in response to increased demand for its products


Augnito to launch ambient technology for clinical documentation
Digitisation | June 23, 2023

Augnito to launch ambient technology for clinical documentation

Augnito’s AI comprehends all English accents with 99% accuracy


Mandaviya inaugurates G20 co-branded event of PMNCH, Geneva on health
News | June 21, 2023

Mandaviya inaugurates G20 co-branded event of PMNCH, Geneva on health

Dignitaries and delegates commend India’s leadership in Global South during G20 India Presidency


Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
interviews | June 20, 2023

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth


USFDA approves Roche’s Columvi for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma
Drug Approval | June 19, 2023

USFDA approves Roche’s Columvi for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma

Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma